Tentative PDL Classes Scheduled For Review At July 2025 DUR Board Meeting Announced
Published on
The following drugs and drug classes are tentatively scheduled for review during the July 25, 2025, Texas Drug Utilization Review Board meeting.
Drug Classes
- Alzheimer’s agents
- Antihistamines, minimally sedating
- Antipsychotics
- Calcium channel blockers (oral)
- Cephalosporins and related antibiotics (oral)
- Fluoroquinolones, oral
- Glucocorticoids, oral
- Immunosuppressives
- Iron, oral
- Leukotriene modifiers
- Non-narcotic analgesics
- Ophthalmic antibiotics
- Ophthalmics antibiotic – steroid combinations
- Ophthalmics for allergic conjunctivitis
- Ophthalmics, anti-inflammatories
- Ophthalmics, anti-inflammatory immunomodulators
- Ophthalmics, glaucoma agents
- Otic antibiotics
- Otic anti-infectives/anesthetics
- Penicillins
- Rosacea agents, topical
- Skeletal muscle relaxants
- Steroids, topical
- Transthyretin-related amyloidosis
- Ulcerative colitis
- Uterine disorder treatment
Single Drugs / PDL Classes
- Gomekli capsule and tablet for susp / Oncology, other- oral
- Onapgo cartridge / Antiparkinson’s agents
- Raldesy solution / Antidepressants, other
- Romvinza capsule / Oncology, other- oral
- Rybelsus (formulation R2 [1.5-, 4-, 9-mg tablets]) / Hypoglycemics, incretin mimetics/enhancers
- Symbravo tablet / Antimigraine agents
- Tryngolza autoinjector / Lipotropics, others
- Xromi solution / Sickle cell anemia treatments